Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda Puts Brakes on High Hopes for TAK-165 Anticancer Agent
April 22, 2002
- 37 New Drugs Officially Approved
April 22, 2002
- Report on Future Trends in Regenerative Medicine Completed
April 22, 2002
- Korosho Presents Bill for Rivision of PAL to Diet
April 22, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 22, 2002
- 1,576 Firms Apply for Disclosure of PFSB Information
April 22, 2002
- Toshiba Forms Alliance with US Heartlab to Market Cardiovascular Information System
April 22, 2002
- REGULATORY NEWS IN BRIEF
April 22, 2002
- Shimadzu Developing Next-generation DNA Sequencers
April 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 22, 2002
- MEDICAL DEVICE NEWS IN BRIEF
April 22, 2002
- Paxil's Sales Top \12 Bil. in 2001
April 22, 2002
- Meiji Seika to Promote Depromel to Non-specialists
April 22, 2002
- Sanofi-Synthelabo Looks for New Type of Partnership in Japan
April 15, 2002
- LDP Opposed to Experimental Deregulation in Healthcare Field
April 15, 2002
- Tamiflu Leads Relenza on Market for Anti-flu Drugs
April 15, 2002
- Copayment Hike to Reduce Patients' Visits to Hospitals: Survey
April 15, 2002
- Entering US Market to Change Business Style of Japanese Firms: Analyst
April 15, 2002
- Awareness of GL on COPD Low
April 15, 2002
- Janssen: Sales Up 28.7% to \41.3 Billion
April 15, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…